Nanotechnology to deliver cannabinoids in dermatology

Adusumilli, Nagasai; Hazuka, Elizabeth; Friedman, Adam

doi:10.33218/001c.24597

Cited by 5 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there is no single conventional treatment that works for all MS patients at all stages, and the limited use of FDA-approved cannabinoids in medical practice is due to the inconsistent efficacy, inadequate targeting, and the absence of a thorough understanding of the stability of commercially available cannabis formulations [ 96 , 116 , 117 ]. Cannabinoids, being lipophilic, have varying oral absorption and distribution levels [ 118 ].…”

Section: Nanomedicine and Cannabinoids For Ms Treatmentmentioning

confidence: 99%

Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine

Nouh,

Kamal,

Oyewole

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Multiple sclerosis is the predominant autoimmune disorder affecting the central nervous system in adolescents and adults. Specific treatments are categorized as disease-modifying, whereas others are symptomatic treatments to alleviate painful symptoms. Currently, no singular conventional therapy is universally effective for all patients across all stages of the illness. Nevertheless, cannabinoids exhibit significant promise in their capacity for neuroprotection, anti-inflammation, and immunosuppression. This review will examine the traditional treatment for multiple sclerosis, the increasing interest in using cannabis as a treatment method, its role in protecting the nervous system and regulating the immune system, commercially available therapeutic cannabinoids, and the emerging use of cannabis in nanomedicine. In conclusion, cannabinoids exhibit potential as a disease-modifying treatment rather than merely symptomatic relief. However, further research is necessary to unveil their role and establish the safety and advancements in nano-cannabinoid medicine, offering the potential for reduced toxicity and fewer adverse effects, thereby maximizing the benefits of cannabinoids.

show abstract

Section: Nanomedicine and Cannabinoids For Ms Treatmentmentioning

confidence: 99%

Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine

Nouh,

Kamal,

Oyewole

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Additionally, the potential promising benefits of applying nanoformulation and nanoencapsulation systems can be improving the effective doses delivery of highly lipophilic drugs (e.g., cannabinoids), protecting poor stable therapeutic agents from aggressive environments, and targeted and controlled delivery [96]. Hence, considering cannabinoids physicochemical limitations, they may benefit from nanotechnology approaches to overcome the Stratum corneum barrier [97,98].…”

Section: Transdermal Delivery Of Cannabinoids and Challengesmentioning

confidence: 99%

The Transdermal Delivery of Therapeutic Cannabinoids

et al. 2022

View full text Add to dashboard Cite

Recently, several studies have indicated an increased interest in the scientific community regarding the application of Cannabis sativa plants, and their extracts, for medicinal purposes. This plant of enormous medicinal potential has been legalised in an increasing number of countries globally. Due to the recent changes in therapeutic and recreational legislation, cannabis and cannabinoids are now frequently permitted for use in clinical settings. However, with their highly lipophilic features and very low aqueous solubility, cannabinoids are prone to degradation, specifically in solution, as they are light-, temperature-, and auto-oxidation-sensitive. Thus, plant-derived cannabinoids have been developed for oral, nasal-inhalation, intranasal, mucosal (sublingual and buccal), transcutaneous (transdermal), local (topical), and parenteral deliveries. Among these administrations routes, topical and transdermal products usually have a higher bioavailability rate with a prolonged steady-state plasma concentration. Additionally, these administrations have the potential to eliminate the psychotropic impacts of the drug by its diffusion into a nonreactive, dead stratum corneum. This modality avoids oral administration and, thus, the first-pass metabolism, leading to constant cannabinoid plasma levels. This review article investigates the practicality of delivering therapeutic cannabinoids via skin in accordance with existing literature.

show abstract

“…Other delivery routes that have yet to be explored are intravenous, intramuscular and intranasal. Emulsions via nanotechnology advances are also aimed at improving the bioavailability of the active molecules in Cannabis ( Holgado et al, 2017 ; Adusumilli et al, 2021 ).…”

Section: Delivery Routesmentioning

confidence: 99%

Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug

et al. 2022

View full text Add to dashboard Cite

Medical Cannabis and its major cannabinoids (−)-trans-Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are gaining momentum for various medical purposes as their therapeutic qualities are becoming better established. However, studies regarding their efficacy are oftentimes inconclusive. This is chiefly because Cannabis is a versatile plant rather than a single drug and its effects do not depend only on the amount of THC and CBD. Hundreds of Cannabis cultivars and hybrids exist worldwide, each with a unique and distinct chemical profile. Most studies focus on THC and CBD, but these are just two of over 140 phytocannabinoids found in the plant in addition to a milieu of terpenoids, flavonoids and other compounds with potential therapeutic activities. Different plants contain a very different array of these metabolites in varying relative ratios, and it is the interplay between these molecules from the plant and the endocannabinoid system in the body that determines the ultimate therapeutic response and associated adverse effects. Here, we discuss how phytocannabinoid profiles differ between plants depending on the chemovar types, review the major factors that affect secondary metabolite accumulation in the plant including the genotype, growth conditions, processing, storage and the delivery route; and highlight how these factors make Cannabis treatment highly complex.

show abstract

Nanotechnology to deliver cannabinoids in dermatology

Cited by 5 publications

References 39 publications

Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine

Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine

The Transdermal Delivery of Therapeutic Cannabinoids

Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug

Contact Info

Product

Resources

About